{"schema_version":"secwatch.filing_event.v1","accession":"0001087294-26-000011","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.521808+00:00","generated_at":"2026-05-16T04:47:55.090008+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cumberland Pharma gets FDA Fast Track for ifetroban in DMD heart disease","bullets":["FDA Fast Track Designation granted for ifetroban targeting fatal heart disease in Duchenne muscular dystrophy.","Designation follows previous Orphan Drug and Rare Pediatric Disease Designations for same indication.","Phase 2 FIGHT DMD trial showed 5.4% improvement in left ventricular ejection fraction over 12 months.","Fast Track enables expedited review, rolling submission, and more frequent FDA interactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001087294-26-000011","json":"https://secwatch.observer/filing/0001087294-26-000011.json","markdown":"https://secwatch.observer/filing/0001087294-26-000011.md","text":"https://secwatch.observer/filing/0001087294-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000011/0001087294-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000011/cpix-20260204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:47:55.090008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}